ABSTRACT

Mucormycosis is a serious infection caused by fungi of the genus Mucor and Rizhopus (order Mucorales, class: Zygomycetes) that occurs in immunocompromised hosts, so it is an opportunistic fungal infection. The enter way is the aspiration from contaminated soil with spores, contamination of wounds or catheters, or by ingestion. The most important clinical presentations are rhinocerebral and lung diseases; the latter being the most reported in children. Diagnosis is difficult, finding hyphae in bronchoalveolar lavage samples, body fluids or biopsies is necessary. The treatment is based on three fundamental aspects: 1) treatment of the underlying disease, 2) antifungal therapy and 3) debridement of necrotic tissue.

KEYWORDS

Pulmonary mucormicosis, children, micosis.

REFERENCES

1. Danion F, Aguilar C, Catherinot E, et al. Mucormycosis: New developments into a persistently devastating infection. Semin Respir Crit Care Med 2015;36(5):692-705. doi: 10.1055/s-0035-1562896.

2. Chayakulkeeree M, Ghannoum MA, Perfect JR. Zygomycosis: the reemerging fungal infection. Eur J Clin Microbiol Infect Dis 2006;25(4):215-229.

3. Vázquez TO, Campos RT, Ovando FJE. Micosis en vías respiratorias en niños. Rev Enfer Infec Pediatr 2011;XXIV(95):88-89.

4. Bonifaz A, Tirado-Sánchez A, Calderón L, et al. Mucormycosis in children: a study of 22 cases in a Mexican hospital. Mycoses 2014;57 Suppl 3:79-84. doi: 10.1111/myc.12233.

5. Munguía CDA, Ochoa GCC, Peña MES, Romo GJ, Téllez BJL. Mucormicosis pulmonar. Presentación de un caso. Neumol Cir Torax 2009;68(2):78-81.

6. Skiada A, Pagano L, Groll A, et al.; European Confederation of Medical Mycology Working Group on Zygomycosis. Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007. Clin Microbiol Infect 2011;17(12):1859-1867. doi: 10.1111/j.1469-0691.2010.03456.x.

7. Chakrabarti A, Chatterjee SS, Das A, et al. Invasive zygomycosis in India: experience in a tertiary care hospital. Postgrad Med J 2009;85(1009):573-581. doi: 10.1136/pgmj.2008.076463.

8. Pagano L, Offidani M, Fianchi L, et al.; GIMEMA (Gruppo Italiano Malattie EMatologiche dell’Adulto) Infection Program. Mucormycosis in hematologic patients. Haematologica 2004;89(2):207-214.

9. Garcia-Hermoso D, Alanio A, Lortholary O, Dromer F. Agents of systemic and subcutaneous mucormycosis and entomophthoromycosis. In: Manual Clinical Microbiology. 11th ed. Washington, DC: ASM Press; 2015.p.2087-2108.

10. Chamilos G, Marom EM, Lewis RE, Lionakis MS, Kontoyiannis DP. Predictors of pulmonary zygomycosis versus invasive pulmonary aspergillosis in patients with cancer. Clin Infect Dis 2005;41(1):60-66.

11. Vogl TJ, Hinrichs T, Jacobi V, Böhme A, Hoelzer D. Computed tomographic appearance of pulmonary mucormycosis. Rofo 2000;172(7):604-608.

12. Wahba H, Truong MT, Lei X, Kontoyiannis DP, Marom EM. Reversed halo sign in invasive pulmonary fungal infections. Clin Infect Dis 2008;46(11):1733-1737. doi: 10.1086/587991.

13. Marty FM, Koo S. Role of (1-->3)-beta-D-glucan in the diagnosis of invasive aspergillosis. Med Mycol 2009;47 Suppl 1:S233-S240. doi: 10.1080/13693780802308454.

14. Lass-Flörl C, Resch G, Nachbaur D, et al. The value of computed tomography-guided percutaneous lung biopsy for diagnosis of invasive fungal infection in immunocompromised patients. Clin Infect Dis 2007;45(7):e101-e104.

15. Millon L, Larosa F, Lepiller Q, et al. Quantitative polymerase chain reaction detection of circulating DNA in serum for early diagnosis of mucormycosis in immunocompromised patients. Clin Infect Dis 2013;56(10):e95-e101. doi: 10.1093/cid/cit094.

16. Saoulidis S, Simitsopoulou M, Dalakiouridou M, et al. Antifungal activity of posaconazole and granulocyte colony-stimulating factor in the treatment of disseminated zygomycosis (mucormycosis) in a neutropaenic murine model. Mycoses 2011;54(5):e486-e492. doi: 10.1111/j.1439-0507.2010.01958.x.

17. Almyroudis NG, Sutton DA, Fothergill AW, Rinaldi MG, Kusne S. In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents. Antimicrob Agents Chemother 2007;51(7):2587-2590.

18. Skiada A, Lanternier F, Groll AH, et al.; European Conference on Infections in Leukemia. Diagnosis and treatment of mucormycosis in patients with hematological malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3). Haematologica 2013;98(4):492-504 doi: 10.3324/haematol.2012.065110.

19. Tedder M, Spratt JA, Anstadt MP, Hegde SS, Tedder SD, Lowe JE. Pulmonary mucormycosis: results of medical and surgical therapy. Ann Thorac Surg 1994;57(4):1044-1050.

20. Roden MM, Zaoutis TE, Buchanan WL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005;41(5):634-653.